Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Gilead Sciences
(NQ:
GILD
)
130.40
-3.24 (-2.42%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 24, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
5,966,100
Open
131.54
Bid (Size)
130.00 (100)
Ask (Size)
130.98 (200)
Prev. Close
133.64
Today's Range
129.28 - 132.32
52wk Range
93.37 - 157.29
Shares Outstanding
1,253,809,440
Dividend Yield
2.42%
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Gilead Sciences Inc (NASDAQ:GILD): A Balanced Dividend Play with Strong Financial Health and Profitability
↗
Today 8:10 EDT
Via
Chartmill
2 Large-Cap Stocks to Consider Right Now and 1 We Turn Down
April 24, 2026
Large-cap stocks have the power to shape entire industries thanks to their size and widespread influence. With such vast footprints, however, finding new are...
Via
StockStory
Performance
YTD
+7.2%
+7.2%
1 Month
-4.7%
-4.7%
3 Month
-5.4%
-5.4%
6 Month
+8.2%
+8.2%
1 Year
+26.4%
+26.4%
More News
Read More
Gilead Sciences to Release First Quarter 2026 Financial Results on Thursday, May 7, 2026
April 22, 2026
From
Gilead Sciences, Inc.
Via
Business Wire
What's Going On With Arcus Biosciences Stock On Wednesday?
↗
April 22, 2026
Via
Benzinga
Eli Lilly Snags $7 Billion Cancer Deal To Rival Gilead, J&J, Others
↗
April 20, 2026
Via
Investor's Business Daily
Gilead Sciences (NASDAQ:GILD): A Value Screen Candidate with Strong Profitability
↗
April 20, 2026
Via
Chartmill
Here's How Much $100 Invested In Gilead Sciences 20 Years Ago Would Be Worth Today
↗
April 14, 2026
Via
Benzinga
PEPFAR and The Global Fund Make Additional Investment in Gilead’s Lenacapavir for HIV Prevention to Further Expand Access
April 14, 2026
From
Gilead Sciences, Inc.
Via
Business Wire
1 Profitable Stock for Long-Term Investors and 2 Facing Challenges
April 14, 2026
Via
StockStory
Q4 Earnings Highs And Lows: Gilead Sciences (NASDAQ:GILD) Vs The Rest Of The Therapeutics Stocks
April 12, 2026
Via
StockStory
Topics
Artificial Intelligence
Gilead Expands Partnership With Tempus AI To Power Cancer Discoveries
↗
April 10, 2026
Via
Benzinga
Topics
Artificial Intelligence
Gilead Sciences Solidifies Oncology Future with $5 Billion Acquisition of ADC Innovator Tubulis
April 09, 2026
Via
MarketMinute
Topics
Bonds
Gilead Expands Tempus AI Partnership To Boost Oncology Pipeline
↗
April 09, 2026
Via
Benzinga
Topics
Artificial Intelligence
Gilead Acquisition Spree Continues With $3 Billion Tubulis Deal
↗
April 07, 2026
Via
Benzinga
Gilead to Acquire Tubulis Adding Potentially Best-in-Class Antibody-Drug Conjugate and Next Generation Platform to Further Strengthen Oncology Pipeline
April 07, 2026
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead Extends Tender Offer for Arcellx as Biotech M&A Sentiment Faces a Reality Check
April 06, 2026
Via
MarketMinute
Gilead Extends Tender Offer to Acquire Arcellx
April 01, 2026
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead Sciences's Q1 2026 Earnings: What to Expect
April 01, 2026
Via
Barchart.com
Topics
ETFs
Workforce
Gilead Sciences Acquires Ouro Medicines for $2.2 Billion to Lead 'Immune Reset' Revolution
March 31, 2026
Via
MarketMinute
Options Action: Naked Put Trade Ideas for March 31
March 31, 2026
Via
Barchart.com
Tango Therapeutics Insider Sells $304,000 in Stock Amid a 36% Single-Day Surge
↗
March 30, 2026
Via
The Motley Fool
Topics
Regulatory Compliance
$1000 Invested In Gilead Sciences 20 Years Ago Would Be Worth This Much Today
↗
March 30, 2026
Via
Benzinga
Gilead Powers Up Its Inflammation Pipeline With Over $1.5 Billion Acquisition
↗
March 24, 2026
Via
Benzinga
Gilead Sciences to Acquire Ouro Medicines to Advance First in Class T Cell Engager Program for Autoimmune Diseases
March 23, 2026
From
Gilead Sciences, Inc.
Via
Business Wire
The Record-Breaking M&A Renaissance of 2026: Why Deal Values are Soaring as Volume Dips
March 19, 2026
Via
MarketMinute
Topics
Artificial Intelligence
Economy
Workforce
Frequently Asked Questions
Is Gilead Sciences publicly traded?
Yes, Gilead Sciences is publicly traded.
What exchange does Gilead Sciences trade on?
Gilead Sciences trades on the Nasdaq Stock Market
What is the ticker symbol for Gilead Sciences?
The ticker symbol for Gilead Sciences is GILD on the Nasdaq Stock Market
What is the current price of Gilead Sciences?
The current price of Gilead Sciences is 130.40
When was Gilead Sciences last traded?
The last trade of Gilead Sciences was at 04/24/26 04:00 PM ET
What is the market capitalization of Gilead Sciences?
The market capitalization of Gilead Sciences is 163.50B
How many shares of Gilead Sciences are outstanding?
Gilead Sciences has 163B shares outstanding.
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.